Clinical trials: Insulin-Like Growth Factor I
Thyroid Eye Disease
An Efficacy, Safety, and Tolerability Study of Veligrotug (VRDN-001), in Participants With Chronic Thyroid Eye Disease (TED)
This is a clinical trial assessing the efficacy, safety, and tolerability of an investigational drug, veligrotug (VRDN-001), in participants with chronic thyroid eye disease (TED).
- Trial name
- THRIVE-2 (NCT06021054)
- Testing
- Veligrotug
- Where
- 57 sites in United States, Australia and 7 more
- Volunteers
- 188 people
- Sponsor
- Viridian Therapeutics, Inc.
HIV, Inflammation
Exercise for Healthy Aging: The Impact of HIV and Aging on Physical Function and the Somatopause
The primary objective of this proposal is to compare a moderate or high intensity exercise intervention to improve physical function in persons aging with Human Immunodeficiency Virus (HIV).
- Conditions
- HIV, Inflammation, Obesity, Aging, Biological
- Trial name
- NCT02404792
- Testing
- High-intensity cardiovascular and resistance exercise, Moderate-intensity cardiovascular and resistance exercise
- Where
- United States
- Volunteers
- 69 people, healthy volunteers welcome
- Sponsor
- University of Colorado, Denver
Diabetes Mellitus, Type 2
Cinnamomum Cassia Effect on IGF1 and Metabolic Control in Patients With DM2 Without Glycemic Control Metformin Treated
Among the multiple treatment options for Diabetes Mellitus Type 2 (DM2), the influence on Insuline like growth factor 1 (IGF1) plays a causal role in diabetes but has shown similarities with insulin, both in its structure and in…
- Trial name
- CICAFAC1 (NCT03610412)
- Testing
- Cinnamomum Cassia
- Where
- Mexico
- Volunteers
- 28 people
- Sponsor
- Coordinación de Investigación en Salud, Mexico
Hepatocellular Carcinoma
A Phase 1 Study of MM-141 in Patients With Advanced Solid Tumors
This study is a Phase 1 and pharmacologic open-labeled dose-escalation trial using a "3+3" design, evaluating MM-141 at varying dose levels and frequencies.
- Trial name
- NCT01733004
- Testing
- MM-141
- Where
- 4 sites in United States, France
- Volunteers
- 42 people
- Sponsor
- Merrimack Pharmaceuticals
Nutritional Supplement
Using IGF-1 for Nutritional Monitoring
Nutrition support is critical to a vast number of patients who are hospitalized annually because of critical illnesses or surgery.
- Trial name
- NCT03277014
- Volunteers
- 197 people
- Sponsor
- Wang Xinying
Severe Adult Growth Hormone Deficiency
Effect of Pegvisomant on GH/IGF-I Relationship in GHD
Approximately 50% of middle-aged patients with severe AGHD have a normal age-related serum IGF-I. It remains unclear if in these individuals serum IGF-I is GH dependent or independent.
- Trial name
- NCT00468624
- Testing
- arginine stimulation test after each limb
- Where
- United Kingdom
- Volunteers
- healthy volunteers welcome
- Sponsor
- The Christie NHS Foundation Trust
Acromegaly
Pasireotide in Patients With Acromegaly Inadequately Controlled With First Generation Somatostatin Analogues
This is a phase IIIb multicenter, open-label; single arm study to evaluate the efficacy and safety of pasireotide LAR 40 mg and 60 mg in patients with inadequately controlled acromegaly with maximal approved doses of first…
- Trial name
- NCT02354508
- Testing
- Pasireotide LAR
- Where
- 50 sites in Argentina, Belgium and 13 more
- Volunteers
- 123 people
- Sponsor
- Novartis Pharmaceuticals
Diminished Ovarian Reserve, Female Infertility
Hippo-Related Competing Endogenous RNA (ceRNA) Network Dysregulation and In Vitro Fertilization (IVF) Outcomes in Women With Diminished Ovarian Reserve
Diminished Ovarian Reserve (DOR) is an important cause of female infertility and is associated with poor ovarian response and lower pregnancy rates during In Vitro Fertilization (IVF).
- Conditions
- Diminished Ovarian Reserve, Female Infertility, In Vitro Fertilization
- Trial name
- DOR-HIPPO-IVF (NCT07658846)
- Where
- Egypt
- Volunteers
- 70 people
- Sponsor
- Assiut University
HER2 Positive Breast Carcinoma, Recurrent Breast Carcinoma
Capecitabine and Lapatinib Ditosylate With or Without Cixutumumab in Treating Patients With Previously Treated HER2-Positive Stage IIIB-IV Breast Cancer
This phase II trial studies capecitabine and lapatinib ditosylate to see how well they work compared with capecitabine, lapatinib ditosylate, and cixutumumab in treating patients with previously treated HER2-positive stage…
- Conditions
- HER2 Positive Breast Carcinoma, Recurrent Breast Carcinoma, Stage IIIB Breast Cancer AJCC v7, Stage IIIC Breast Cancer AJCC v7
- Trial name
- NCT00684983
- Testing
- Capecitabine, Cixutumumab, Lapatinib Ditosylate
- Where
- 390 sites in United States
- Volunteers
- 64 people
- Sponsor
- National Cancer Institute (NCI)
Androgen Receptor Abnormal, Insulin-Like Growth Factor I Deficiency
AR, IGF-IR, IR and Peripheral Artery Disease
Peripheral artery Disease (PAD) is a major cardiovascular disease that can impair quality of life (QoL). It affects more often male patients and its pathophysiology is not completely known.
- Conditions
- Androgen Receptor Abnormal, Insulin-Like Growth Factor I Deficiency, Insulin Receptor, Defect in
- Trial name
- ANIMALPAD (NCT04710186)
- Testing
- arterial reconstructive open surgery
- Where
- Italy
- Volunteers
- 30 people
- Sponsor
- University of Catanzaro
Recurrent Adrenocortical Carcinoma, Stage III Adrenocortical Carcinoma
IMC-A12 With Mitotane vs Mitotane Alone in Recurrent, Metastatic, or Primary ACC That Cannot Be Removed by Surgery
This randomized phase II trial is studying mitotane and IMC-A12 to see how well they work compared with mitotane alone in treating patients with recurrent, metastatic, or primary adrenocortical cancer that cannot be removed by…
- Conditions
- Recurrent Adrenocortical Carcinoma, Stage III Adrenocortical Carcinoma, Stage IV Adrenocortical Carcinoma
- Trial name
- NCT00778817
- Testing
- IMC-A12, mitotane
- Where
- 8 sites in United States
- Volunteers
- 20 people
- Sponsor
- National Cancer Institute (NCI)